DK0951908T3 - Behandling af impotens på grund af rygmarvsskade - Google Patents

Behandling af impotens på grund af rygmarvsskade

Info

Publication number
DK0951908T3
DK0951908T3 DK99301085T DK99301085T DK0951908T3 DK 0951908 T3 DK0951908 T3 DK 0951908T3 DK 99301085 T DK99301085 T DK 99301085T DK 99301085 T DK99301085 T DK 99301085T DK 0951908 T3 DK0951908 T3 DK 0951908T3
Authority
DK
Denmark
Prior art keywords
spinal cord
cord injury
treatment
impotence due
male
Prior art date
Application number
DK99301085T
Other languages
English (en)
Inventor
Murray Craig Maytom
Ian Howard Osterloh
Original Assignee
Pfizer Ireland Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ireland Pharmaceuticals filed Critical Pfizer Ireland Pharmaceuticals
Application granted granted Critical
Publication of DK0951908T3 publication Critical patent/DK0951908T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Electrotherapy Devices (AREA)
DK99301085T 1998-02-23 1999-02-15 Behandling af impotens på grund af rygmarvsskade DK0951908T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7558098P 1998-02-23 1998-02-23

Publications (1)

Publication Number Publication Date
DK0951908T3 true DK0951908T3 (da) 2004-12-27

Family

ID=22126701

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99301085T DK0951908T3 (da) 1998-02-23 1999-02-15 Behandling af impotens på grund af rygmarvsskade

Country Status (17)

Country Link
US (1) US20060040935A1 (da)
EP (1) EP0951908B1 (da)
JP (1) JPH11315025A (da)
KR (1) KR19990072798A (da)
AT (1) ATE279194T1 (da)
AU (1) AU755402B2 (da)
CA (1) CA2262268C (da)
DE (1) DE69921008T2 (da)
DK (1) DK0951908T3 (da)
ES (1) ES2226281T3 (da)
HU (1) HUP9900438A3 (da)
IL (1) IL128532A0 (da)
MY (1) MY133446A (da)
NZ (1) NZ334333A (da)
PT (1) PT951908E (da)
TW (1) TW542719B (da)
ZA (1) ZA991393B (da)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403597B1 (en) 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
US6548490B1 (en) * 1997-10-28 2003-04-15 Vivus, Inc. Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
GT199900061A (es) * 1998-05-15 2000-10-14 Pfizer Formulaciones farmaceuticas.
US6200591B1 (en) 1998-06-25 2001-03-13 Anwar A. Hussain Method of administration of sildenafil to produce instantaneous response for the treatment of erectile dysfunction
DE19834506A1 (de) * 1998-07-31 2000-02-03 Hexal Ag Transmucosales therapeutisches System zur Anwendung von Sildenafil
DE19834507A1 (de) * 1998-07-31 2000-02-03 Hexal Ag Pharmazeutische, wasserlösliche Tablettenformulierung zur Anwendung von Sildenafil
AU4663100A (en) 1999-04-30 2000-11-17 Lilly Icos Llc Treatment of female arousal disorder
KR20020062770A (ko) 1999-12-24 2002-07-29 바이엘 악티엔게젤샤프트 이미다조 1,3,5 트리아지논 및 그의 용도
KR20010016165A (ko) * 2000-11-16 2001-03-05 정순학 성기능 장애 치료를 위한 피부에 적용하는 제제
KR100393160B1 (ko) * 2001-06-14 2003-07-31 한국과학기술연구원 신규한 피라졸로피리미딘티온 유도체, 그의 제법 및발기부전 치료제로서의 용도
WO2002102385A1 (en) * 2001-06-14 2002-12-27 Sampad Bhattacharya Compositions comprising cgmppde5 inhibitor for transdermal delivery to the erectile tissue of the penis
JP2007537247A (ja) 2004-05-11 2007-12-20 エモーショナル ブレイン ビー．ブイ． 女性性的機能不全の治療における薬学的製剤およびその使用方法
EP1790343A1 (en) * 2005-11-11 2007-05-30 Emotional Brain B.V. Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction
EP1925307A1 (en) * 2006-11-03 2008-05-28 Emotional Brain B.V. Use of 3-alpha-androstanediol in the treatment of sexual dysfunction
WO2008142396A1 (en) * 2007-05-18 2008-11-27 Anthony Denis Maher Methods of assessing male fertility using a uridine marker

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9114760D0 (en) * 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
GB9301192D0 (en) * 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
GB9423911D0 (en) * 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents

Also Published As

Publication number Publication date
CA2262268A1 (en) 1999-08-23
AU755402B2 (en) 2002-12-12
MY133446A (en) 2007-11-30
DE69921008T2 (de) 2006-02-02
ATE279194T1 (de) 2004-10-15
HUP9900438A2 (hu) 2000-03-28
EP0951908B1 (en) 2004-10-13
PT951908E (pt) 2005-01-31
IL128532A0 (en) 2000-01-31
DE69921008D1 (de) 2004-11-18
NZ334333A (en) 2000-11-24
AU1839099A (en) 1999-09-09
ES2226281T3 (es) 2005-03-16
HU9900438D0 (en) 1999-04-28
KR19990072798A (ko) 1999-09-27
TW542719B (en) 2003-07-21
ZA991393B (en) 2000-08-22
CA2262268C (en) 2003-07-29
US20060040935A1 (en) 2006-02-23
HUP9900438A3 (en) 2002-01-28
EP0951908A3 (en) 2000-08-16
JPH11315025A (ja) 1999-11-16
EP0951908A2 (en) 1999-10-27

Similar Documents

Publication Publication Date Title
DK0951908T3 (da) Behandling af impotens på grund af rygmarvsskade
AR016993A1 (es) Formulaciones intranasales para tratar trastornos sexuales
MX9703868A (es) Inhibidores de cgmp-pde para el tratamiento de disfuncion erectil.
IL153492A0 (en) Treatment of male sexual dysfunction
ITMI20020990A0 (it) Formulazioni utili nel trattamento dell'impotenza maschile e femminile
EP1108426A3 (en) Use of prostaglandin agonists to treat erectile dysfunction or impotence
AR025569A1 (es) Pirazol [4,3-d] pirimidinas
ID24184A (id) Obat untuk perawatan disfungsi ereksi
PT1109814E (pt) 5-heterociclil pirazol¬4,3-d|pirimidina-7-onas para o tratamento da disfuncao erectil masculina
DK1150698T3 (da) Anvendelser af vaskulær endotelvækstfaktor i behandlingen af erektil dysfunktion
NO20062883L (no) Fosfodiesterase-V-inhibitorpreparater
HUP0400528A2 (hu) Neuropeptidáz Y inhibitor alkalmazása férfiak szexuális funkciózavarának kezelésére alkalmas gyógyszerkészítmény előállítására
AU2001281396A1 (en) Novel compositions and methods for treatment of male erectile dysfunction
ECSP993027A (es) Formulaciones intranasales para trastornos sexuales
ES2092685T3 (es) Uso de atipamezol para el tratamiento de impotencia sexual masculina.
GB9928178D0 (en) Agent for the treatment of male and female sexual dysfunction
GB0030647D0 (en) Treatment of male sexual dysfunction
CA2203379A1 (en) Cgmp-pde inhibitors for the treatment of erectile dysfunction
SI1505997T1 (sl) Farmacevtske oblike, uporabne za zdravljenje moske in zenske impotence
GB0108730D0 (en) Treatment of male sexual dysfunction
GB0108483D0 (en) Treatment of male sexual dysfunction
GB0120679D0 (en) Treatment of male sexual dysfunction
GB0106167D0 (en) Treatment of male sexual dysfunction